by Donarys Cruz
Experts from over 20 countries will attend Havana 2010 Biotechnology Congress to be held October 20 through 22 at Havana’s Convention Palace. The event will address the use of Heberprot-P in the treatment of diabetic foot ulcers.
The paper “Dealing with adverse effects related with Heberprot-P in the State of Bolivar, Venezuela 2009” by Sancti Spiritus’s Dr. Rafael Ibargollin Ulloa and Dr. Yanet Hernandez Jimenez, currently in Venezuela, will be presented at the congress by the research’s Venezuelan co-authors.
According to the coordinator of the Heberprot-P national program, some 150 specialists have confirmed attendance to the event as well as 200 Cuban experts.
Since 2007 until present moment, 4 000 Cuban diabetic patients have reported improvement after being Heberprot-P treated. The medication has been also used in patients from Venezuela, Algeria, Argentina, Dominican Republic, Uruguay, Angola and Libya.
Heberprot-P is a Cuban biotechnology industry made product which favors the healing of deep ulcers and reduces the risk of amputation. The medication is currently available in every Cuban hospital and is being extended to primary care health institutions.
This medication was registered in Cuba in June 2006 and less than one year later (April 2007) it was included in the country’s basic scheme of drugs.
Heberprot-P national extension program was started in June 2007 and Sancti Spiritus was one of the Cuban territories selected for the demonstration.